Headlines about IDEXX Laboratories (NASDAQ:IDXX) have been trending somewhat positive on Thursday, Accern reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. IDEXX Laboratories earned a coverage optimism score of 0.07 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.9406621550478 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news articles that may have impacted Accern’s rankings:
Several research firms have issued reports on IDXX. BidaskClub upgraded IDEXX Laboratories from a “sell” rating to a “hold” rating in a research report on Friday, January 5th. Aegis reiterated a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price target on the stock in a report on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price target on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Finally, Canaccord Genuity restated a “buy” rating and issued a $180.00 price target on shares of IDEXX Laboratories in a report on Friday, October 6th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $173.67.
Shares of IDEXX Laboratories (NASDAQ:IDXX) opened at $166.14 on Thursday. The firm has a market capitalization of $14,490.00, a P/E ratio of 53.94, a P/E/G ratio of 2.29 and a beta of 0.42. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. IDEXX Laboratories has a fifty-two week low of $116.54 and a fifty-two week high of $173.01.
IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The firm had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. During the same quarter in the prior year, the company earned $0.62 EPS. IDEXX Laboratories’s revenue was up 9.7% on a year-over-year basis. analysts expect that IDEXX Laboratories will post 3.24 earnings per share for the current year.
In other IDEXX Laboratories news, insider Giovani Twigge sold 2,000 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $156.07, for a total transaction of $312,140.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $153.61, for a total value of $2,764,980.00. Following the transaction, the chief executive officer now directly owns 1,064,573 shares in the company, valued at approximately $163,529,058.53. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,000 shares of company stock worth $16,686,200. 2.77% of the stock is owned by corporate insiders.
WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/01/11/idexx-laboratories-idxx-earns-daily-news-sentiment-rating-of-0-07.html.
About IDEXX Laboratories
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.